Phase 1 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give their signed agreement to participate in the trial
• People aged 18 to 75 years old at the time of screening
• People whose life expectancy is more than 12 weeks
• People who have been diagnosed with multiple myeloma (MM) according to recognised international guidelines
• People whose disease meets at least one of the following measurable levels: a certain amount of abnormal protein (M protein) detected in the blood or urine, or abnormal levels of light chain proteins in the blood, or tumour growths outside the bone marrow larger than 1 cm
• For the dose-escalation part of Phase I: people who have had at least 3 previous treatment courses, have previously received a treatment that targets a protein called BCMA, and whose disease stopped responding to their most recent treatment
• For the dose-expansion part of Phase I and for Phase II: people who have previously received a BCMA-targeting treatment, such as a BCMA bispecific antibody (e.g., teclistamab), a BCMA antibody-drug conjugate (e.g., BLENREP), or a BCMA CAR-T cell therapy (e.g., CARVYKTI)
• People whose blood counts, kidney, liver, lung, and heart function are at acceptable levels
• People (and their partners) who are willing to use effective contraception until 2 years after receiving the trial treatment

Who may not be able to join:

• People who are pregnant or breastfeeding
• People who have tested positive for HIV, or who have an active Hepatitis B or Hepatitis C infection
• People who have a known history of the cancer spreading to the brain or spinal cord (central nervous system)
• People who have a history of an autoimmune disease (such as Crohn's disease, rheumatoid arthritis, or lupus) that has caused organ damage or required ongoing immune-suppressing medication in the past 2 years
• People who currently have an uncontrolled active infection
• People who received a stem cell transplant using their own stem cells (autologous) within the 8 weeks before screening, or who plan to have this procedure during the study
• People who have previously received a stem cell transplant using another person's stem cells (allogeneic)
• People who have any other condition that the trial doctor believes would interfere with evaluating the trial treatment (confirm with trial site)
• People who received a chemotherapy drug called Bendamustine within the 1 year before screening

Important: Always verify eligibility with the trial site directly before applying.